Fortitude Advisory Group L.L.C. Buys Shares of 75,740 Metagenomi, Inc. (NASDAQ:MGX)

Fortitude Advisory Group L.L.C. acquired a new stake in shares of Metagenomi, Inc. (NASDAQ:MGX) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 75,740 shares of the company’s stock, valued at approximately $273,000. Fortitude Advisory Group L.L.C. owned about 0.20% of Metagenomi at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in MGX. Novo Holdings A S increased its holdings in shares of Metagenomi by 3.5% in the second quarter. Novo Holdings A S now owns 1,800,000 shares of the company’s stock valued at $7,344,000 after purchasing an additional 60,825 shares during the period. Geode Capital Management LLC lifted its holdings in Metagenomi by 105.8% during the third quarter. Geode Capital Management LLC now owns 338,031 shares of the company’s stock valued at $734,000 after purchasing an additional 173,796 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its holdings in Metagenomi by 209.4% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 136,624 shares of the company’s stock worth $296,000 after buying an additional 92,468 shares during the last quarter. Marquette Asset Management LLC acquired a new stake in shares of Metagenomi in the fourth quarter worth approximately $184,000. Finally, Verition Fund Management LLC purchased a new stake in shares of Metagenomi during the third quarter worth $82,000.

Metagenomi Trading Down 6.7 %

Shares of NASDAQ MGX opened at $2.77 on Tuesday. The business has a 50 day simple moving average of $2.95 and a 200-day simple moving average of $2.89. Metagenomi, Inc. has a twelve month low of $1.61 and a twelve month high of $12.74.

Analyst Ratings Changes

A number of analysts have issued reports on the company. HC Wainwright raised their target price on Metagenomi from $7.00 to $14.00 and gave the stock a “buy” rating in a research note on Tuesday, December 10th. Chardan Capital reissued a “buy” rating and issued a $15.00 price objective on shares of Metagenomi in a research note on Wednesday, November 20th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $16.67.

Metagenomi Company Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.